Company / R&D Expense
AXIM BIOTECHNOLOGIES, INC. R&D Expense History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$125.5K
FY2023
5-year range
$125.5K / $2.1M
FY2019-FY2023
Trend
-18.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2M to $125,496 over the past 5 years.
Based on SEC 10-K filings.
$125,496 in FY2023 with a 5-year CAGR of -42.8%.
Declined from $2M to $125,496 over the past 5 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -42.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -42.8%, indicating a declining trend.
- In FY2023, r&d expense decreased 18.3% year-over-year.
- Peak r&d expense was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $125.5K | -18.3% |
| FY2022 | $153.7K | -92.5% |
| FY2018 | $2.1M | +52.0% |
| FY2017 | $1.4M | +474.3% |
| FY2016 | $235.6K | -58.8% |
| FY2015 | $571.5K | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026